REC-4881

Recursion Pharmaceuticals Inc. · Phase 2 active Small molecule

At a glance

Generic name	REC-4881
Sponsor	Recursion Pharmaceuticals Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation (PHASE2)
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

REC-4881 CI brief — competitive landscape report
REC-4881 updates RSS · CI watch RSS
Recursion Pharmaceuticals Inc. portfolio CI